Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-02 in CRPS-I
NCT02504008Phase 3Unknown
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jul 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in complex regional pain syndrome type I (CRPS) comparing AXS-02 with Placebo (2 arms). Primary endpoint: Change in patient reported pain intensity at 12 weeks. Status: unknown.
02
Drugs
zoledronate
03
Conditions
complex regional pain syndrome type I (CRPS)
Beyond the preview
Go deeper on NCT02504008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504008.